Revolution Medicines. has filed a patent for macrocyclic compounds that inhibit Ras proteins, potentially offering a new treatment for cancers. The patent claims cover the specific compounds and their pharmaceutical compositions. GlobalData’s report on Revolution Medicines gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Revolution Medicines Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Revolution Medicines, Cancer treatment biomarkers was a key innovation area identified from patents. Revolution Medicines's grant share as of January 2024 was 14%. Grant share is based on the ratio of number of grants to total number of patents.

Inhibiting ras proteins for cancer treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Revolution Medicines Inc

A recently filed patent (Publication Number: US20230374035A1) includes claims related to a compound or pharmaceutically acceptable salt thereof for treating cancer and Ras protein-related disorders. The patent claims cover a pharmaceutical composition containing the compound along with a pharmaceutically acceptable excipient, as well as methods for treating cancer and Ras protein-related disorders by administering the compound to a subject in need.

Specifically, the patent claims mention treating various types of cancer, including pancreatic, colorectal, lung, gastric, esophageal, ovarian, and uterine cancer, especially those with Ras mutations at specific positions such as 12, 13, or 61. The compound mentioned in the claims targets Ras mutations like K-Ras G12C, K-Ras G12D, K-Ras G12V, K-Ras G12S, K-Ras G13C, K-Ras G13D, or K-Ras Q61L, either individually or in combination. The patent also covers stereoisomers of the compound and their pharmaceutically acceptable salts, providing a broad scope for potential therapeutic applications in the field of oncology and Ras protein-related disorders.

To know more about GlobalData’s detailed insights on Revolution Medicines, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies